Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Pancreatic Neoplasms 3Solid Tumors 2Hypoxia 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumor 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neuroectodermal Tumors, Primitive 1Neoplasms 1Melanoma 1Liver Neoplasms 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Kidney Neoplasms 1Gastrointestinal Stromal Tumors 1Esophageal Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1

Interventions

TH 302 2Bacterial Load 2NVP-BKM120 1Ipilimumab 1AQ4N 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Hypoxia × TH 302 × Clear all
NCT03098160 2017-10-30

Immunotherapy Study of Evofosfamide in Combination With Ipilimumab

Threshold Pharmaceuticals

Phase 1 Unknown
69 enrolled
DermatologicGastrointestinalGenitourinaryHead & Neck

Squamous Cell Carcinoma of Head and Neck, Hypoxia, Melanoma, Pancreatic Neoplasms, Prostatic Neoplasms

NCT00495144 2012-07-27

A Phase I Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of TH-302 in Patients With Advanced Solid Tumors

Threshold Pharmaceuticals

Phase 1 Completed
129 enrolled

Hypoxia, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡